Associated tags: NPS, Central nervous system, ChromeOS, CNS, Clinical data management, IRT, Pharmaceutical industry, Patient, Clinical trial, Cros, OR, Guest appearance
Locations: PENNSYLVANIA
Research,
Central nervous system,
Life,
American Opportunity Tax Credit,
ChromeOS,
Patient,
Comprehension,
CNS,
Systematic review,
FAQ,
Clinical trial,
Customer advisory council PHILADELPHIA, March 19, 2024 /PRNewswire/ -- Suvoda LLC, a leading global clinical trial technology company specializing in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, today launched the latest version of its eConsent solution to further enhance the patient experience and ease the patient's journey through a clinical trial.
Key Points:
- Suvoda customers identified these enhancements as critical in helping to minimize delays and, more importantly, to help patients make informed decisions about their clinical trial participation.
- "The latest Suvoda eConsent release is the next step in improving the patient experience," said E.K.
- "Research with sponsors, clinicians, and patients shows that this eConsent solution will help streamline the clinical trial process by increasing patient comprehension," added Koh.
- Learn more about features and benefits of Suvoda eConsent:
Research,
Central nervous system,
Life,
American Opportunity Tax Credit,
ChromeOS,
Patient,
Comprehension,
CNS,
Systematic review,
FAQ,
Clinical trial,
Customer advisory council PHILADELPHIA, March 19, 2024 /PRNewswire/ -- Suvoda LLC, a leading global clinical trial technology company specializing in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, today launched the latest version of its eConsent solution to further enhance the patient experience and ease the patient's journey through a clinical trial.
Key Points:
- Suvoda customers identified these enhancements as critical in helping to minimize delays and, more importantly, to help patients make informed decisions about their clinical trial participation.
- "The latest Suvoda eConsent release is the next step in improving the patient experience," said E.K.
- "Research with sponsors, clinicians, and patients shows that this eConsent solution will help streamline the clinical trial process by increasing patient comprehension," added Koh.
- Learn more about features and benefits of Suvoda eConsent:
Friction,
Clinical trial,
American Opportunity Tax Credit,
ChromeOS,
CNS,
Growth,
Investment,
Central nervous system,
Patient,
UAT,
Pharmaceutical industry PHILADELPHIA, Jan. 8, 2024 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, surpassed 1,400 clinical trials in 2023, and grew sales by 30% year-over-year, signaling broad acceptance of the company's new unified clinical trial platform focusing on the mission-critical and time sensitive moments on the clinical trial patient journey.
Key Points:
- Suvoda made significant investments in its technology platform and offerings in 2023, including the launch of a low-code/no-code application design layer.
- Organically built to deliver the next generation of Suvoda solutions, the Suvoda Platform was designed to handle complexity with ease, reduce overall risk throughout trials, and address real challenges facing clinical trial professionals.
- "We continue to set ourselves apart by staying true to our focus on delivering with excellence and being a true partner and trusted advisor to our customers.
- The company also continues to boast 100% on-time delivery across the board.
Friction,
Clinical trial,
American Opportunity Tax Credit,
ChromeOS,
CNS,
Growth,
Investment,
Central nervous system,
Patient,
UAT,
Pharmaceutical industry PHILADELPHIA, Jan. 8, 2024 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, surpassed 1,400 clinical trials in 2023, and grew sales by 30% year-over-year, signaling broad acceptance of the company's new unified clinical trial platform focusing on the mission-critical and time sensitive moments on the clinical trial patient journey.
Key Points:
- Suvoda made significant investments in its technology platform and offerings in 2023, including the launch of a low-code/no-code application design layer.
- Organically built to deliver the next generation of Suvoda solutions, the Suvoda Platform was designed to handle complexity with ease, reduce overall risk throughout trials, and address real challenges facing clinical trial professionals.
- "We continue to set ourselves apart by staying true to our focus on delivering with excellence and being a true partner and trusted advisor to our customers.
- The company also continues to boast 100% on-time delivery across the board.
Retrieved on:
Thursday, November 9, 2023
FDA,
Smartphone,
IRT,
Reading,
American Opportunity Tax Credit,
Data collection,
Certification,
Doctor of Philosophy,
CNS,
Patient,
ISPOR,
Software,
Nature,
Usability,
PRO,
Central nervous system,
Medical device,
Nursing PHILADELPHIA, Nov. 9, 2023 /PRNewswire/ -- Suvoda LLC, a leading global clinical trial technology company specializing in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, has successfully conducted usability testing of its electronic clinical outcomes assessment (eCOA) solution in collaboration with RWS Life Sciences. The study resulted in the certification of Suvoda eCOA as highly usable and effective for the patient population.
Key Points:
- The study resulted in the certification of Suvoda eCOA as highly usable and effective for the patient population.
- Suvoda announced the general availability of its eCOA product in May 2023 to address the difficulties and delays associated with traditional eCOA products.
- And, because Suvoda eCOA, IRT, and eConsent are delivered on a single platform, study teams benefit from improved data integrity.
- "This study validates that our eCOA solution makes it easy and efficient to obtain quality patient outcomes data for submissions and approvals."
Retrieved on:
Thursday, November 9, 2023
FDA,
Smartphone,
IRT,
Reading,
American Opportunity Tax Credit,
Data collection,
Certification,
Doctor of Philosophy,
CNS,
Patient,
ISPOR,
Software,
Nature,
Usability,
PRO,
Central nervous system,
Medical device,
Nursing PHILADELPHIA, Nov. 9, 2023 /PRNewswire/ -- Suvoda LLC, a leading global clinical trial technology company specializing in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, has successfully conducted usability testing of its electronic clinical outcomes assessment (eCOA) solution in collaboration with RWS Life Sciences. The study resulted in the certification of Suvoda eCOA as highly usable and effective for the patient population.
Key Points:
- The study resulted in the certification of Suvoda eCOA as highly usable and effective for the patient population.
- Suvoda announced the general availability of its eCOA product in May 2023 to address the difficulties and delays associated with traditional eCOA products.
- And, because Suvoda eCOA, IRT, and eConsent are delivered on a single platform, study teams benefit from improved data integrity.
- "This study validates that our eCOA solution makes it easy and efficient to obtain quality patient outcomes data for submissions and approvals."
Retrieved on:
Thursday, October 12, 2023
Partnership,
Central nervous system,
Organization,
Advanced Drug Delivery Reviews,
Carbon,
Failure,
Buffer,
Clinical trial,
IRT,
CNS,
Pharmaceutical industry,
Dietary supplement,
Fine chemical PHILADELPHIA, Oct. 12, 2023 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, announced a new Advanced Drug Optimization feature as part of its latest Interactive Response Technology (IRT) release. This new functionality offers sponsors of clinical drug trials improved drug supply management, delivering cost savings and helping companies to reduce their carbon footprint.
Key Points:
- This new functionality offers sponsors of clinical drug trials improved drug supply management, delivering cost savings and helping companies to reduce their carbon footprint.
- Suvoda introduces Advanced Drug Optimization for IRT to improve accuracy of clinical trial drug supply management.
- Traditionally, drug supply strategies have relied on static quantities of initial drug shipments and buffers, often leading to excessive orders to ensure enough medication is available during a trial.
- And, Advanced Drug Optimization gives us more tools to help our joint customers meet their drug supply needs in ways that better support their clinical trial and organizational goals."
Retrieved on:
Thursday, October 12, 2023
Partnership,
Central nervous system,
Organization,
Advanced Drug Delivery Reviews,
Carbon,
Failure,
Buffer,
Clinical trial,
IRT,
CNS,
Pharmaceutical industry,
Fine chemical PHILADELPHIA, Oct. 12, 2023 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, announced a new Advanced Drug Optimization feature as part of its latest Interactive Response Technology (IRT) release. This new functionality offers sponsors of clinical drug trials improved drug supply management, delivering cost savings and helping companies to reduce their carbon footprint.
Key Points:
- This new functionality offers sponsors of clinical drug trials improved drug supply management, delivering cost savings and helping companies to reduce their carbon footprint.
- Traditionally, drug supply strategies have relied on static quantities of initial drug shipments and buffers, often leading to excessive orders to ensure enough medication is available during a trial.
- The Advance Drug Optimization feature aligns with Suvoda's mission to deliver purpose-built e-clinical solutions that give sponsors command over trials with complex drug supply management needs.
- And, Advanced Drug Optimization gives us more tools to help our joint customers meet their drug supply needs in ways that better support their clinical trial and organizational goals."
Retrieved on:
Thursday, September 14, 2023
Civic,
Xerox,
Heart,
Amazon,
Growth,
Palace of Culture,
Central nervous system,
Accenture,
Civic center,
Student,
Environment,
CNS,
Oracle PHILADELPHIA, Sept. 14, 2023 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, has expanded its presence in Romania with the opening of its newest office in Iași.
Key Points:
- Suvoda's Iași office, which officially opened in July, will house teams specializing in product development, software engineering, and professional services, with plans to expand into other areas as the company grows.
- Palas Iași, where the Suvoda office is situated, is a prime mixed-use development located in the heart of Iași's Civic Centre district, in proximity to the iconic Palace of Culture.
- Iași, the third largest city in Romania, is known as a vibrant academic center, boasting five public universities and approximately 60,000 students.
- "As Suvoda's presence in Romania continues to grow, this new office helps us deliver on our commitment to nurture an environment of collaboration and belonging."
Central nervous system,
CAB,
Clinical data management,
American Opportunity Tax Credit,
Culture,
Public,
Biotechnology,
Neurodegenerative disease,
New York Medical College,
Element,
IRT,
CNS,
Science,
Biometrics,
Patient,
Novo Nordisk,
IDH1,
Knowledge,
Shirin David,
Cardiology,
Therapy,
Psychiatry,
Neurology,
Pharmaceutical industry,
Nursing PHILADELPHIA, June 20, 2023 /PRNewswire/ -- Suvoda LLC , a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, has tapped Irena Lerentracht Webster to join its board of directors.
Key Points:
- PHILADELPHIA, June 20, 2023 /PRNewswire/ -- Suvoda LLC , a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, has tapped Irena Lerentracht Webster to join its board of directors.
- Webster is a seasoned global drug development leader with over two decades of experience at sponsor, CRO, and site levels.
- She has led global clinical trial strategy and execution in a myriad of therapeutic areas including neurology, psychiatry, oncology, cardiology, and rare disease, contributing to multiple NDAs and sNDAs.
- In addition to joining the board of directors, Webster also serves on the Suvoda customer advisory board (CAB).
